Uniteversity Muliprofile Hospital For Active Treatment Tsaritsa Yoanna-Isul EAD
- Address
- lock Available on a paid plan
Cardiovascular Research
At the Clinic of Cardiology in Uniteversity Muliprofile Hospital For Active Treatment Tsaritsa Yoanna-Isul EAD, a major focus is cardiovascular disease research. The studies include acute coronary syndrome, atrial fibrillation, and broader atherosclerotic cardiovascular disease, with the goal of improving prevention of serious events and evaluating new treatment options.
- Testing therapies aimed at lowering the risk of heart attack, stroke, and cardiovascular death
- Studying treatment options for atrial fibrillation when standard anticoagulation is not suitable
- Assessing approaches for patients with elevated lipoprotein(a) and other high-risk cardiovascular profiles
These trials reflect an active effort in cardiovascular medicine to improve outcomes for patients at high risk of recurrent events.
Neurology and Imaging Diagnostics
Another important area at this hospital is diagnostic imaging, especially studies of contrast agents used in magnetic resonance imaging. Research includes both central and non-central nervous system applications, with attention to how safely and effectively imaging tools support diagnosis.
- Evaluating new contrast agents for better MRI performance
- Studying imaging support for suspected brain, spinal cord, and other body system conditions
- Including pediatric research to improve diagnostic care in children
The site’s work in diagnostics aims to strengthen the accuracy and safety of imaging for a range of clinical needs.
Hematology and Bleeding Disorders
Research in hemic and lymphatic diseases at this site includes studies in haemophilia A and haemophilia B. These trials focus on long-term control of bleeding disorders and on understanding joint health in patients receiving preventive treatment.
- Monitoring joint outcomes in people with haemophilia on prophylactic therapy
- Investigating long-term safety of newer preventive treatments
- Extending research to very young patients with severe haemophilia A
This line of research supports better day-to-day management and safer care for patients living with inherited bleeding conditions.
Gastroenterology and Inflammatory Bowel Disease
The site is also involved in digestive system diseases research, particularly Crohn’s disease and ulcerative colitis. These studies are designed to compare treatment effectiveness, improve symptom control, and support longer-term disease management in adults with active inflammatory bowel disease.
- Comparing therapies for moderate to severe Crohn’s disease
- Evaluating improvement in bowel inflammation and symptom relief in ulcerative colitis
- Following longer-term safety in patients who continue treatment
Work in gastroenterology here is centered on finding more effective ways to control chronic intestinal inflammation.
Metabolic and Weight-Related Cardiovascular Research
Studies in nutritional and metabolic diseases at this site include research on obesity and related cardiovascular risk. The main aim is to assess whether new treatment approaches can help reduce major heart and vessel complications in people with excess weight or metabolic risk factors.
- Examining cardiovascular safety and benefit in people with overweight or obesity
- Exploring whether treatment can lower the risk of major adverse cardiovascular events
- Linking metabolic health with prevention of heart disease outcomes
This research connects metabolism and cardiology to address long-term health risks more effectively.
Specialized Therapeutic Innovation
The site’s broader portfolio also includes studies in analytical, diagnostic and therapeutic techniques and equipment, reflecting interest in new tools and treatment strategies across multiple diseases. These trials are designed to test emerging therapies and improve how conditions are detected and managed in routine care.
- Evaluating new treatment options across several chronic diseases
- Improving diagnostic precision and clinical decision-making
- Supporting research that links advanced technologies with patient care
This diverse activity shows the Sofia site’s role in both disease-focused and technology-driven clinical research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 130 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 129 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniteversity Muliprofile Hospital For Active Treatment Tsaritsa Yoanna-Isul EAD
lock Showing 1 of 82 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 130 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2024-05-22 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
